Ionis Pharmaceuticals

News
FDA building

FDA delays decision on Biogen's ALS hope tofersen

The FDA is planning to take an additional three months to review Biogen's experimental therapy for amyotrophic lateral sclerosis (ALS), setting back its decision date from January to April.